---
title: "HCW Biologics reports positive Phase 1 readout for HCW9302; 3/3 responders at 3 µg/kg, no serious IL-2 toxicities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289910833.md"
description: "HCW Biologics reported positive Phase 1 data for HCW9302 in alopecia areata. All three participants at 3 µg/kg showed ≥25% SALT score reduction with no serious IL-2 toxicities or dose-limiting adverse events. The company aims to establish the recommended Phase 2 dose by year-end 2026."
datetime: "2026-06-16T11:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289910833.md)
  - [en](https://longbridge.com/en/news/289910833.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289910833.md)
---

# HCW Biologics reports positive Phase 1 readout for HCW9302; 3/3 responders at 3 µg/kg, no serious IL-2 toxicities

**HCW Biologics announced positive preliminary Phase 1 human data for HCW9302 showing clinical improvement and a favorable safety profile.**

**Key Highlights:**

-   First two dose cohorts in dose‑escalation Phase 1 showed positive preliminary human data for HCW9302 in alopecia areata.
-   All three participants at 3 µg/kg had ≥25% reduction in SALT scores at 4 and/or 9 weeks after a single subcutaneous dose.
-   No dose‑limiting toxicities or serious IL‑2‑related adverse effects reported, including no capillary leak, cytokine release, or rise in eosinophils.
-   Most adverse events were mild, self‑limiting injection‑site reactions; company aims to establish recommended Phase 2 dose by year‑end 2026.

Original SEC Filing: HCW Biologics Inc. \[ HCWB \] - 8-K - Jun. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md)

## Related News & Research

- [HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering | HCWB Stock News](https://longbridge.com/en/news/294214489.md)
- [Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs](https://longbridge.com/en/news/294362509.md)
- [Hyperscalers can't win with investors as they spend big on AI](https://longbridge.com/en/news/293912231.md)
- [ACOMO: Strong H1 results, resilient margins, and strategic growth despite global uncertainties](https://longbridge.com/en/news/294082652.md)
- [SHARDACROP: Revenue increased but net profit and EPS declined, with seasonality impacting results](https://longbridge.com/en/news/294177010.md)